| abstract |
Compounds derived from 1,2,4-oxadiazole as TRPA1 inhibitors, pharmaceutical compositions comprising them and the use thereof for the treatment of diseases or conditions mediated by TRPA1 activity. Claim 1: A compound of formula (1) or a pharmaceutically acceptable salt thereof, characterized in that: A is: substituted or unsubstituted 6-6 fused bicyclic heteroaryl which may be partially saturated; 5-6 substituted or unsubstituted fused bicyclic heteroaryl which may be partially saturated; or substituted and unsubstituted 6-5 fused bicyclic heteroaryl which may be partially saturated; X is; a link; C₁₋₄ alkylene; -OR-; -S-; -SO₂-; or -N (Rᵃ) -; n is: 0, 1, 2 or 3; Rᵃ is H or C₁₋₆ alkyl which may be unsubstituted or which may be substituted one or more times with halo; R¹ is: H; or C₁₋₆ alkyl; and R⁴ is: substituted or unsubstituted phenyl; substituted or unsubstituted heteroaryl; or substituted or unsubstituted naphthyl; or R¹ and R⁴ may together form an unsubstituted or substituted C₃₋₆ cycloalkyl fused to a substituted or unsubstituted phenyl; substituted or unsubstituted heteroaryl; or substituted or unsubstituted naphthyl. |